A drug already in use for several cancers was found effective in a study of leptomeningeal dissemination of cancer.
149 13th Street
Charlestown, MA 02129
Hours: Monday–Friday, 8:00 am–6:00 pm
Explore This Research Lab
About the Lab
A major research goal of the Arnaout Laboratory is to elucidate the structure and function of integrins, cell adhesion receptors that play vital roles in normal physiology and disease and use the derived information in structure-based design of new and safer anti-integrin drugs targeting heart disease, fibrosis, and cancer.
Other research interests include elucidating mechanisms underlying cyst formation in Autosomal Dominant Polycystic Kidney Disease, transcriptional regulation of hematopoiesis, mechanisms of kidney regeneration, and design of microfluidic dialysis devices.
- View Dr. Arnaout's Harvard Stem Cell Institute Profile
- View Dr. Arnaout's Harvard Catalyst Profile
- Developmental and Regenerative Biology (DRB) Graduate Program
- Center for Regenerative Medicine
- Atomic structure of the integrin aVb3 in complex with macromolecular ligands
- Structure-based design of novel anti-integrin therapeutics
- EM structure of the leukocyte integrin CD11b/CD18 (aMb2)
- Role of adaptor proteins in regulation of leukocyte integrins
- Role of integrins in ischemia-reperfusion injury models
- Mechanisms of cyst formation in Autosomal Dominant Polycystic Kidney Disease
- Mechanisms of renal injury and regeneration
- Development of microfluidic devices for dialysis
- Transcriptional regulation of hematopoiesis
If you are interested in applying for a postdoctoral position, or are a Harvard PhD student interested in a laboratory rotation, please e-mail your CV (for student and postdoctoral) and reference letters (for postdoctoral) to: email@example.com
- Insights From New Study May Lead to Safer Drugs (Mass General press release)
- Dr. Arnaout was elected as member in the prestigious American Clinical and Climatological Association (ACCA) in Oct. 2019. Members of the ACCA comprise outstanding physicians selected on the basis of their leadership, scientific excellence, high level of integrity and professionalism. Active membership is limited to 250 physicians.
- Dr. Arnaout has received the 2018 Homer W. Smith Award from the American Society of Nephrology (ASN). Read more on the Research Institute blog, and the Harvard Medical School website.
- Dr. Arnaout has received the 2017 Kuwait Prize in Applied Medical Sciences from the KFAS. Read more in the MGH Awards and Honors newsletter.
- Mass General study finds a "Goldilocks" drug that prevents chronic kidney disease in primates — Massachusetts General Hospital News Articles, January 10, 2017
- Solving the problem of shape shifters — Harvard Gazette, 25 March 2014
- Cell Signaling: The MIDAS Touch — Nature Reviews, Molecular Cell Biology, May 2002
- Role Found for Protein in Kidney Disease — Harvard FOCUS, 12 January 2001
- Cell Adhesion Receptor Caught on Bended Knee — Havard FOCUS, 14 September 2001
- An Anthropomorphic Integrin —Science, 12 October 2001
- Integrin Binding Revealed — Nature Structural Biology, 2:181 1998
- Press Release
- Jun | 2 | 2020
A team led by investigators at Mass General and the Broad Institute of MIT and Harvard recently found that applying “polygenic risk scores” can identify at-risk patients who are not presently identified through standard clinical evaluations.
- Press Release
- May | 15 | 2020
A team led by researchers from Mass General has uncovered key molecular step stones in alcohol-related liver disease that may provide targets for drug therapy development.
- May | 1 | 2020
The National Institute of Allergy and Infectious Diseases (NIAID) reported April 29 that preliminary data from the study indicates that patients with advanced COVID-19 symptoms who received remdesivir recovered 31% faster than similar patients who received a placebo.
- May | 1 | 2020
- Mar | 27 | 2020
El Dr. Raghu Chivukula, MD, PhD, explica lo que se sabe actualmente sobre la droga y su uso para tratar a los pacientes con el COVID-19.
About the Nephrology Division
The Division of Nephrology at Massachusetts General Hospital is a leading provider of services for patients with kidney disease, including diagnosis and management of kidney diseases and medical management of renal transplantation.